$NDRA

ASP Isotopes plans to merge its subsidiary Noble Africa, which holds South Africa’s Renergen helium and LNG project, with ENDRA Life Sciences to form a publicly listed helium platform called Noble Africa. ASP Isotopes expects ~89% ownership post-close. Management cites 1P helium reserves of 7.2 Bcf and targets Phase 1 output of ~70 Mcf/day helium and 2,500 GJ/day LNG, with estimated revenue and cash gross profit. Closing is targeted for Q4, subject to SEC review and approvals.

ASP Isotopes (NASDAQ:ASPI) and ENDRA Life Sciences (NASDAQ:NDRA) said RedChip will host a July 21, 2026 webinar on Noble Africa, an ASP Isotopes subsidiary holding Renergen’s Virginia Gas Project. The proposed merger with ENDRA could list Noble Africa on Nasdaq as NOBA. CEO Paul Mann will discuss helium and LNG plans, including Phase 1 ramp in 2026.

ENDRA Life Sciences Inc. (NDRA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 ea029523901ex2-1.htm AGREEMENT AND PLAN OF MERGER, DATED AS OF JUNE 25, 2026, BY AND AMONG ENDRA LIFE SCIENCES INC., KRUGER MERGER SUB LLC, RENERGEN LIMITED, NOBLE AFRICA LLC AND ASP ISOTOPES INC Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among ASP ISOTOPES INC., NO

ENDRA Life Sciences (NASDAQ: NDRA) is distinguishing itself through its combination of breakthrough medical imaging innovation, specifically the TAEUS® system for liver disease, and a next-generation treasury strategy managed by Arca Investment Management. This strategy aims to improve capital efficiency and accelerate growth by transforming idle cash into a yield-generating engine. The company's TAEUS® system targets steatotic liver disease and MASH, a massive and underdiagnosed market, aligning with the rapidly expanding GLP-1 therapy market.

Endra Life Sciences Inc. (NASDAQ:NDRA) announced that its shareholders approved a significant increase in authorized common stock from 20 million to 1 billion shares, alongside the election of four directors, at its 2025 annual meeting. Shareholders also ratified the appointment of RBSM LLP as the independent accounting firm and approved executive compensation on an advisory basis, but rejected a proposal for officer exculpation. These decisions reflect ongoing corporate governance activities and strategic initiatives, including advancements in the TAEUS Liver device and a recent $4.9 million PIPE financing to enhance financial stability and technological capabilities.

ENDRA Life Sciences (NASDAQ: NDRA) is advancing its TAEUS® liver imaging technology, which offers a cost-effective alternative to MRI for diagnosing steatotic liver disease and MASH. The company is also enhancing its capital efficiency through a partnership with Arca Investment Management, generating non-dilutive returns to support clinical validation and commercialization. Recent feasibility study results confirm TAEUS®'s alignment with MRI-PDFF performance, positioning ENDRA for significant market impact in both clinical care and pharmaceutical development.

ENDRA Life Sciences Inc. ( NASDAQ:NDRA ) shares jumped after the company announced $4.9 million in funding commitments from institutional and cryptocurrency investors to launch a new digital asset treasury strategy.

Shares of ENDRA Life Sciences Inc. NDRA rose sharply in pre-market trading after the company announced it will be granted a US patent titled "Radio Frequency Applicator". ENDRA Life Sciences shares jumped 61.4% to $5.58 in the pre-market trading session. Here are some other stocks moving in ...